Xencor | XNCR - Pasivo Circulante





Pasivo Circulante Cambio Fecha
AbbVie USD 42.1B 1.19B 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
Arrowhead Research USD 295.22M 52.2M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
Biogen USD 3B 350.5M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Cytokinetics USD 199.18M 3.27M 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
J&J USD 57.72B 3.59B 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
MacroGenics USD 95.94M 52.82M 2026-03
Merck USD 26.94B 1.38B 2026-03
Novartis USD 31.37B 4.1B 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Xencor USD 73.46M 22.45M 2026-03